Methadyl acetate

DB01433

small molecule experimental illicit

Deskripsi

A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.

Struktur Molekul 2D

Berat 353.4977
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

915 Data
Buprenorphine Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.
Hydrocodone Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.
Magnesium sulfate The therapeutic efficacy of Methadyl acetate can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Methadyl acetate may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.
Orphenadrine Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.
Pramipexole Methadyl acetate may increase the sedative activities of Pramipexole.
Ropinirole Methadyl acetate may increase the sedative activities of Ropinirole.
Rotigotine Methadyl acetate may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Methadyl acetate.
Sodium oxybate Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.
Thalidomide Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Alvimopan The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Alvimopan.
Desmopressin The risk or severity of hyponatremia can be increased when Methadyl acetate is combined with Desmopressin.
Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Methadyl acetate.
Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Methadyl acetate.
Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methadyl acetate.
Meperidine The risk or severity of adverse effects can be increased when Meperidine is combined with Methadyl acetate.
Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Methadyl acetate.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methadyl acetate.
Naltrexone The therapeutic efficacy of Methadyl acetate can be decreased when used in combination with Naltrexone.
Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Methadyl acetate.
Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Methadyl acetate.
Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Methadyl acetate.
Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Methadyl acetate.
Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Methadyl acetate.
Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methadyl acetate.
Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Methadyl acetate.
Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Diamorphine.
Bezitramide The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Bezitramide.
Ethylmorphine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Dihydromorphine.
Ketobemidone The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Methadyl acetate is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Nicomorphine.
Meptazinol The therapeutic efficacy of Methadyl acetate can be decreased when used in combination with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Carfentanil, C-11.
Naloxegol The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Naloxegol.
Benzhydrocodone The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Benzhydrocodone.
Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadyl acetate.
Succinylcholine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Methadyl acetate.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Methadyl acetate.
Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Methadyl acetate.
Mirtazapine Methadyl acetate may increase the serotonergic activities of Mirtazapine.
Fluvoxamine The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Fluvoxamine.
Citalopram The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Citalopram.
Duloxetine The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Duloxetine.
Paroxetine The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Paroxetine.
Sertraline The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Sertraline.
Sibutramine The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Sibutramine.
Nefazodone The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Nefazodone.
Zimelidine The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Zimelidine.
Dapoxetine The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Dapoxetine.
Milnacipran The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Milnacipran.
Desvenlafaxine The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Methadyl acetate.
Seproxetine The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Seproxetine.
Levomilnacipran The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Levomilnacipran.
Indalpine The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Indalpine.
Ritanserin The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Ritanserin.
Alaproclate The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Alaproclate.
Ethanol Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Methadyl acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.
Phentermine Phentermine may increase the analgesic activities of Methadyl acetate.
Pseudoephedrine Pseudoephedrine may increase the analgesic activities of Methadyl acetate.
Benzphetamine Benzphetamine may increase the analgesic activities of Methadyl acetate.
Diethylpropion Diethylpropion may increase the analgesic activities of Methadyl acetate.
Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Lisdexamfetamine.
Mephentermine Mephentermine may increase the analgesic activities of Methadyl acetate.
MMDA MMDA may increase the analgesic activities of Methadyl acetate.
Midomafetamine Midomafetamine may increase the analgesic activities of Methadyl acetate.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Methadyl acetate.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Methadyl acetate.

Target Protein

Mu-type opioid receptor OPRM1

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul